11 patents currently held
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Feb 2039. from the record
Of the 4 now held by other companies, 3 name Regeneron Pharmaceuticals Inc. as their current owner, and 1 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Feb 2039
Next term end
6
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jun 2041 · High confidence
Also notable
Ends Feb 2039 · Medium confidence
Also notable
Ends Feb 2039 · Medium confidence
Compositions and Methods for Treating Sensorineural Hearing Loss Using Otoferlin Dual Vector Systems
US 11,660,353
The most cited patent in this portfolio, cited by 9 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2041.
Hypertonic Pharmaceutical Compositions Containing an Anti-Platinum Chemoprotectant Agent
US 10,709,732
A family of 6 related applications built on the 2020 grant. Protection runs to 2039.
Methods of Otoprotection Against Platinum-Based Antineoplastic Agents
US 11,690,870
The newest of the three, granted 2023. It anchors the portfolio to 2039, later than anything else here. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 4, 2027The maintenance fee for Methods of Otoprotection Against Platinum-Based Antineoplastic Agents (US 11,690,870) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Hypertonic Pharmaceutical Compositions Containing an Anti-Platinum Chemoprotectant Agent (US 11,857,567) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 20, 2026
What they patent
The 5 largest of its 6 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methods of Otoprotection Against Platinum-Based Antineoplastic Agents | 3 in force | to Feb 2039 |
| Hypertonic Pharmaceutical Compositions Containing an Anti-Platinum Chemoprotectant Agent | 3 in force | to Feb 2039 |
| Compositions and Methods for Treating Sensorineural Hearing Loss Using Otoferlin Dual Vector Systems | 2 in force | to Jun 2041 |
| Cochlear Inner Hair Cell Promoters and Uses Thereof | 1 in force | to Nov 2042 |
| AAV1 Vectors and Uses Thereof for Treatment of Otic Indications | 1 in force | to Jun 2042 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,709,732 | Hypertonic Pharmaceutical Compositions Containing an Anti-Platinum Chemoprotectant Agent In force · Medium confidence | In force | Medium confidence | |
| US 10,813,947 | Methods of Otoprotection Against Platinum-Based Antineoplastic Agents In force · High confidence | In force | High confidence | |
| US 11,071,751 | Hypertonic Pharmaceutical Compositions Containing an Anti-Platinum Chemoprotectant Agent In force · Low confidence | In force | Low confidence | |
| US 11,690,870 | Methods of Otoprotection Against Platinum-Based Antineoplastic Agents In force · Medium confidence | In force | Medium confidence | |
| US 11,857,567 | Hypertonic Pharmaceutical Compositions Containing an Anti-Platinum Chemoprotectant Agent In force · Low confidence | In force | Low confidence | |
| US 12,653,838 | Methods of Otoprotection Against Platinum-Based Antineoplastic Agents In force · Medium confidence | In force | Medium confidence | |
| US 12,741,034 | Compositions and Methods for Treating Sensorineural Hearing Loss Using Otoferlin Dual Vector Systems In force · High confidence | In force | High confidence | |
| US 11,660,353 | Compositions and Methods for Treating Sensorineural Hearing Loss Using Otoferlin Dual Vector Systems In force · High confidence | In force | High confidence | |
| US 12,233,136 | Myosin 15 Promoters and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,534,739 | AAV1 Vectors and Uses Thereof for Treatment of Otic Indications In force · High confidence | In force | High confidence |
Also on record, not counted in the 11: 4 patents in force now held by others · 26 applications pending · 2 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.